Non-alcoholic fatty liver, adipose tissue, and the bone: A new triumvirate on the block

Endocrine

Volumn 42, Issue 2, 2012, Pages 237-239

  Musso, Giovanni ^a  

^a GRADENIGO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; INSULIN; LEPTIN; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; VITAMIN D;

ADIPOSE TISSUE; BONE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE MINERALIZATION; BONE REMODELING; DISEASE ASSOCIATION; ENERGY BALANCE; ENERGY METABOLISM; HUMAN; INSULIN RESISTANCE; MESENCHYMAL STEM CELL; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 84867375204     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9748-2     Document Type: Review

References (22)

1. D. von Muhlen, S. Safii, S.K. Jassal, J. Svartberg, E. Barrett-Connor, Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos. Int. 18, 1337-1344 (2007)
2. F.J.A. de Paula, M.C. Horowitz, C.J. Rosen, Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab. Res. Rev. 26, 622-630 (2010)
3. C.B. Confavreux, Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int. 79(Suppl 121), S14-S19 (2011)
4. G. Musso, R. Gambino, M. Cassader, G. Pagano, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617-649 (2011)
5. S.S. Moon, Y.S. Lee, S.W. Kim, Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine (2012). doi:10.1007/s12020-012-9639-6
6. R.M. Campos, A. de Piano, P.L. da Silva, J. Carnier, P.L. Sanches, F.C. Corgosinho et al., The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine (2012). doi:10.1007/s12020-012-9613-3
7. P.E. Pardee, W. Dunn, J.B. Schwimmer, Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment. Pharmacol. Ther. 35, 248-254 (2012)
8. K. Brochu-Gaudreau, C. Rehfeldt, R. Blouin, V. Bordignon, B.D. Murphy, M.F. Palin, Adiponectin action from head to toe. Endocrine 37, 11-32 (2010)
9. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58-69 (2012)
10. K. Fulzele, R.C. Riddle, D.J. Digirolamo, X. Cao, C. Wan, D. Chen et al., Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142, 309-319 (2010)
11. G. Musso, M. Cassader, F. Rosina, R. Gambino, Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55, 885-904 (2012)
12. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006)
13. T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi et al., Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784-788 (2009)
14. A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, R.L. Jilka, Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146, 1226-1235 (2005)
15. L.R. McCabe, Understanding the pathology and mechanisms of type 1 diabetic bone loss. J. Cell. Biochem. 102(6), 1343-1357 (2007)
16. M.L. Olson, N.M. Maalouf, J.D. Oden, P.C. White, M.R. Hutchison, Vitamin D deficiency in obese children and its relationship to glucose homeostasis. J. Clin. Endocrinol. Metab. 97(1), 279-285 (2012)
17. B.J. Boucher, Vitamin D insufficiency and diabetes risks. Curr. Drug Targets. 12, 61-87 (2011)
18. A. Birendinc, M. Abawi, M. Stepanova, A. Afendy, A. Baranova, Z. Goodman et al., Vitamin D may be protective against apoptosis in patients with nonalcoholic steatohepatitis (NASH). J. Hepatol. 56(S2), S501-S502 (2012)
19. M. Mahmud, I. Abdullah, R. Ghantous, J. Amer, Low vitamin D levels in nonalcoholic fatty liver disease associate with insulin resistance and liver injury progression via immune NK mechanisms. J. Hepatol. 56(S2), S503 (2012)
20. D. Kim, G.E. Chung, S.H. Lim, J.I. Yim, M.J. Park, Serum vitamin D is inversely associated with nonalcoholic fatty liver disease in general population. J. Hepatol. 56(S2), S511 (2012)
21. N.C. Bozkurt, E. Cakal, M. Sahin, E.C. Ozkaya, H. Firat, T. Delibasi, The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine 41, 518-525 (2012)
22. T. Nakano, Y.F. Cheng, C.Y. Lai, L.W. Hsu, Y.C. Chang, J.Y. Deng et al., Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J. Hepatol. 55, 415-425 (2011)